Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Isis Climbs on Spinal Muscular Atrophy Drug Study

By Pharmaceutical Processing | September 20, 2013

Shares of Isis Pharmaceuticals advanced yesterday after the company reported positive results from a study of a drug designed to treat spinal muscular atrophy, a rare genetic disorder.

Isis said most of the children who received the largest doses of its drug ISIS-SMN continued to show improvements in muscle function up to 14 months after treatment. The study involved 24 children between the ages of 2 and 14 who had type 1, 2, or 3 of spinal muscular atrophy. Each child received a single injection of the drug.

Isis Pharmaceuticals Inc. shares picked up $4.25, or 13.4 percent, to $36.05 in afternoon trading. The stock has more than doubled in value over the last year, and earlier Thursday it reached a 13-year high of $36.38.

Spinal muscular atrophy is a disorder that causes muscle atrophy and weakness. Symptoms generally develop a few months after birth. Patients with the most severe type of the disease generally live less than two years. Patients with less severe forms may still have a severely shortened lifespan and may never be able to stand on their own.

Based on the results, Isis said it will test a larger dose of the drug in an active mid-stage study involving infants. The Carlsbad, Calif., company wants to start late-stage testing of ISIS-SMN in early 2014.

Isis is developing ISIS-SMN with Biogen Idec Inc.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE